Avacta Group Plc (AVCTF PINK) stock market data APIs
$0.3994
0(0%)
as of June 20, 2025
Try our APIs with
free plan!
Avacta Group Plc Financial Data Overview
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.
Prev. Close
0.3994
Open
0.3994
High
0.3994
Low
0.3994
52 wk Range
0.4011-1.3293
Market Cap
158 M
Shares Outstanding
387 M
Revenue
113 K
Beta
-0.284
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Avacta Group Plc data using free add-ons & libraries
Get Avacta Group Plc Fundamental Data
Avacta Group Plc Fundamental data includes:
- Net Revenue: 113 K
- EBITDA: -30 367 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-06
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Avacta Group Plc News
New
Avacta Group reports FY results
* Avacta Group Plc press release [https://avacta.com/preliminary-results-for-the-year-ended-december-31-2024/] (OTCPK:AVCTF [https://seekingalpha.com/symbol/AVCTF]): FY loss per ordinary share from ...
Investors in Avacta Group (LON:AVCT) have made a incredible return of 538% over the past three years
For us, stock picking is in large part the hunt for the truly magnificent stocks. But when you hold the right stock for the right time period, the rewards can be truly huge. For example, the Avacta Gr...
Avacta Group Plc (LON:AVCT) is favoured by institutional owners who hold 58% of the company
If you want to know who really controls Avacta Group Plc (LON:AVCT), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 58...
Avacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug Administration
LONDON & WETHERBY, England, September 05, 2022--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affi...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
